We are live on ! Find out more
RCEL icon

Avita Medical

16.50 USD
+0.42
2.61%
At close Updated Oct 28, 4:00 PM EDT
Pre-market
After hours
16.50
0.00
0%
1 day
2.61%
5 days
8.84%
1 month
41.39%
3 months
257.92%
6 months
281.06%
Year to date
375.5%
1 year
350.82%
5 years
-0.42%
10 years
-55.82%
 

About: Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Employees: 226

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 22.2%
Neutral 77.8%
Negative 0%
Neutral
GlobeNewsWire
8 days ago
AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026.
AVITA Medical to Announce Third Quarter 2026 Financial Results
Neutral
Seeking Alpha
17 days ago
Leading Indicators For The October Breakout Cycle
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
Leading Indicators For The October Breakout Cycle
Neutral
Seeking Alpha
1 month ago
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
1 month ago
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer | New York Morgan Stanley 24th Annual Global Healthcare Conference – Wednesday, September 16, 2026 | 1:05 p.m.
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Positive
Zacks Investment Research
2 months ago
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Positive
Seeking Alpha
2 months ago
AVITA Medical: Favorable Reimbursements For Skin Wound Care
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
AVITA Medical: Favorable Reimbursements For Skin Wound Care
Neutral
MarketBeat
2 months ago
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Neutral
Seeking Alpha
2 months ago
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
Neutral
GlobeNewsWire
2 months ago
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
Price charts implemented using Lightweight Charts™